Back

    Vertical Growth

    Expanding and Scaling Sponsor Accounts in Clinical Research in 2026

    Taylor Crook headshot
    May 26, 2026·~5 min read·Updated July 1, 2026
    life sciencescontract research organizationsclinical trialsaccount growthstrategic accounts

    In clinical research, next year's revenue is already sitting inside your current sponsor accounts. Whether you keep it at the next rebid depends on relationship depth that active billings can hide until it is too late.

    Expanding and Scaling Sponsor Accounts in Clinical Research in 2026

    A CRO can hold a sponsor's business for years, deliver study after study, and still lose the relationship at the next rebid without ever seeing it coming. The programs were running, the teams were busy, the invoices were paid, and then a competitor took the next set of work. Nothing in the day-to-day signaled the loss until it had already happened.

    This is the particular way growth slips in clinical research, and it shapes how a strategic account team should think about expanding and scaling sponsor accounts.

    The economics reward depth, and hide its absence

    Clinical research runs on long, embedded relationships. Work flows under multi-year master service agreements, individual programs run for years, and switching a CRO in the middle of a Phase III trial is something sponsors avoid at almost any cost. The Tufts Center for the Study of Drug Development estimated in 2024 that a Phase III trial costs roughly $55,700 a day to run, so the disruption of changing providers mid-program is measured in millions before a single relationship factor is considered.

    That embeddedness is the strength of the business and the thing that hides its weakness. Because a sponsor rarely switches mid-program, a CRO can keep delivering active studies while its standing with that sponsor quietly weakens. The active work masks the erosion. The signal that matters, whether the sponsor will choose the provider for the next program, does not show up in current billings or active backlog. It shows up at the rebid, when the decision is already being made and it is too late to change the inputs.

    Scaling a sponsor account, then, is the work of building and protecting relationship depth in the window before the rebid, not the work of winning the next proposal once it arrives.

    Depth is multi-stakeholder, and that is where it gets lost

    A sponsor relationship is not one relationship. A large pharma program is evaluated by clinical operations, procurement, medical and clinical development, data management, regulatory, and the executives who own the portfolio. Each of these forms its own view of a provider over years of working together, and the next award depends on the balance of those views.

    A provider can be strong with the program team and thin everywhere else. The clinical operations contacts may be satisfied while procurement has come to see the provider as difficult on change orders, or while the medical team has never built a relationship with the provider at all. Each of those is a quiet gap, and any one of them can decide a rebid. The strength of a single relationship, however good, does not tell a strategic account team how the whole account will break when the decision comes.

    This is why expanding a sponsor account starts with reading it. Before a team can sell into the account, it has to know where each of those relationships actually stands, which ones are strong, which are shallow, and which shallow one is sitting in front of the next major program.

    Read the account across every dimension that decides the rebid

    Building depth deliberately starts with an honest assessment of where the account stands across the areas that determine its future. The Vitality Index organizes this into seven: the strength of the foundation, including the contracts and the delivery track record; the depth of relationships across all the stakeholders who shape an award, not just the program team; competitiveness against the incumbent or preferred providers already inside the sponsor; the room to expand into new programs and therapeutic areas; how the two organizations collaborate through trial execution; the predictability of the account and its future work; and the provider's reputation inside the sponsor, especially on the recruitment and timeline performance that sponsors weigh most heavily.

    Assessed honestly, most sponsor accounts show strength in some of these and gaps in others. The purpose of the assessment is to find the gap that matters most: the shallow relationship, the unaddressed stakeholder, the therapeutic area where the provider has credibility it has not pressed, the program coming up for award where the provider's standing is weaker than the active work suggests.

    Work the gaps in the order that compounds

    Closing those gaps works as a sequence. A provider with a strong delivery record and a real reputation for solving recruitment and timeline risk has proof it can carry to stakeholders it has not yet reached. That proof, translated into the outcomes a medical or executive sponsor cares about, earns relationships beyond the program team. Those relationships make the provider credible when procurement and clinical leadership weigh the next award. And every program won deepens the foundation and widens the relationships for the one after it.

    Worked this way, depth compounds. A provider that has built real standing across the stakeholders who decide awards is not waiting for the next rebid to find out where it stands. It has been building the relationship that wins the rebid for the eighteen months before the proposal was ever written.

    Where Vitality Index fits

    The reason this work so often goes undone is that the account is hard to see clearly. A strategic account team carrying a full book of sponsor relationships rarely has a structured read on where each account truly stands across all of those stakeholders, which gap matters most, or which program is at risk before the rebid arrives.

    At Match Vertical Partners, we built the Vitality Index to give CRO strategic account teams that read. It assesses where a provider stands inside each sponsor account across the seven areas of the relationship, produces a baseline score that shows where the account is strong and where it is exposed, and turns that into a plan to close the gaps in the order that compounds, in the window when there is still time to change the outcome.

    Next year's revenue is already inside your current sponsor accounts. With a clear read on where each one stands, a team can protect and grow it before the rebid decides it.

    See the Vitality Index applied to your accounts. Schedule a 30-minute demo.

    Taylor Crook headshot
    May 26, 2026·~5 min read·Updated July 1, 2026

    More in Vertical Growth

    Vertical Growth

    How Freight Broker Sales Teams Move a Shipper Account From Transactional to Strategic

    Shippers are signaling they want strategic partners, not vendors. Building that partnership inside a shipper account is deliberate work, and the brokers who do it grow accounts the rate-quoters cannot hold.

    Vertical Growth

    How Freight Broker Sales Teams Can Lead Where Shippers Are Already Headed

    Shippers are signaling exactly what they want from a freight partner in 2026: flexibility, total value, and a relationship that performs. The brokers who read those signals and lead there win the accounts that price-quoters cannot hold.

    Vertical Growth

    How AI Services Sales Teams Can Sell Where Buyers Have Actually Moved To

    Enterprise AI buyers have already seen the demos and run the pilots. What they want now is partners who can deliver production, prove value, and own the outcome alongside them. That is the sale, and the firms that lead there are claiming the accounts.

    Vertical Growth

    How AI Services Sales Teams Grow an Enterprise Account Into a Strategic AI Partnership

    An AI services firm that delivered one production-grade win has a chance most of the market does not: a credible foundation for becoming the enterprise's AI partner of record. Building that partnership is deliberate work, and the firms that do it claim the accounts.

    Vertical Growth

    How Reps Can Grow a Health-System Account Into a Strategic Partnership

    Health systems are giving more work to fewer vendors. The accounts that win that expanded scope are the ones a rep has grown into a real partnership, not the ones that were handed off and left to run. Here is how to do the growing.

    Vertical Growth

    How Reps Can Protect a Health-System Account Before the Next Vendor Review

    In healthcare, switching vendors is hard enough that a low churn rate can make an account look safe when it is not. Here is how to find the accounts that are drifting and re-engage them before the next vendor review, when the decision is already made and a lost account rarely comes back.

    Related across the blog

    Lead with better systems.

    The same frameworks that power this post power Vitality Index - the platform strategic account teams use to measure, plan, and grow their most vital partnerships.